• China's New Tiered Bank Accounts

    China's New Tiered Bank Accounts

    One of the big changes in China's banking industry in 2017 was the introduction of bank account type. A new report from Kapronasia looks at the implications.
  • The Future History of Payments from Kapronasia sponsored by Finastra

    The Future History of Payments from Kapronasia sponsored by Finastra

    A new report looks at the key opportunities and challenges in a rapidly changing global payments environment.
  • Research Calendar 2018

    Research Calendar 2018

    The Kapronasia 2018 Research Calendar has been published, contact us to receive a copy and subscribe.
  • National Security & Fintech in China

    National Security & Fintech in China

    China's outbound M&A is failing due to National Security implications around the world. What's happening and why it matters for the financial industry.
  • 1
  • 2
  • 3
  • 4

Latest Reports

After an eventful year with many notable developments in the burgeoning field of fintech, our 8th annual Top-10 Asia Pacific Fintech Trends Report, released in conjunction with the webinar, features an in depth analysis of the 10 most important fintech trends to look out for in Asia this year.
Even as the entire financial industry changes rapidly, nowhere has the change been as evident as in the payments segment. Around the world, banks, consumers, and businesses are making a shift in the way they exchange value.
Most of the research into real-time payments has focused on potential new revenue streams and business models for banks to serve traditional retail and commercial customers. Although this research is valuable, it overlooks an essential segment of the population: the underbanked and financially excluded. Until now.


November 30, 2017 - Dec 01, 2017
Inside Fintech - Seoul
December 13, 2017
Australian Payment Summit
February 15, 2018
Baltic E-commerce Summit - Tallinn
March 13, 2018 - Mar 15, 2018
Money 20/20 Asia Singapore
March 21, 2018 - Mar 22, 2018
Payments Summit 2018 - Helsinki
March 27, 2018 - Mar 28, 2018
MoneyLive: Digital Banking APAC 2018
June 04, 2018
Money 20/20 Europe - Amsterdam
September 22, 2018
Sibos Sydney

Kapronasia is a leading provider of financial industry market research and consulting covering fintech, payments, banking, capital markets and blockchain.


Research From our offices across the region, we provide clients with the key insight and research they need to understand the market trends and challenges. Our research reports are used by numerous clients across the globe to make better business decisions about their Asia strategy.


Consulting We work closely with clients to better understand their business challenges and find lasting and value creating solutions. We have worked with some of the financial industry's largest players to help them re-define their business and drive growth.

A quick note on the GlaxoSmithKline inquiry in China

Written by Zennon Kapron 25 Jul 2013 25 Jul 2013

Although it's completely outside of our area of focus (beyond being China related), we have been getting a number of questions from clients and Kapronasia followers about the situation at GlaxoSmithKline (GSK) and so I thought we should give a bit of background, our position, and the relevance to China's FSI. 


If you haven't been following the news, very briefly, the Chinese government has accused GSK of bribing doctors and hospitals to take their products in exchange for trips and cash incentives allegedly facilitated by a local travel company. Shocker...  Some thoughts:

Firstly, this practice is growing increasingly rare, but is not-unheard of. In China, multinationals for years have operated through middlemen to, for lack of a better word, bribe local authorities, regulators and potential customers. Whether the intermediary was a marketing company, travel agent, or consultant, the agent would give the MNC a bit of arm's length to conduct business in what was once the only way of doing business in China.

Secondly, I find it very hard to believe that senior management outside of China did not know that this was happening. Bribes are rife in the pharma industry throughout the world and China has been known to be corrupt. If you can seriously say that you had no idea it was happening, you should be in a different job. To say that you/the company don't condone it, ok, not aware of it, impossible - don't throw your people under the bus and claim ignorance.

Thirdly, this is part of a Chinese government crackdown on corruption in China that is unlikely to abate anytime soon. If you are operating somehow illegally here, this is a sign that you need to change and change soon as both national and global companies are being monitored and investigated.

Finally, that vigilance is not limited to the pharma industry. Having been involved in the financial technology space here in China for nearly 10 years, we have seen graft and corruption. Whether it's revenue smoothing, over-inflated expenses or R&D centre visits ('really, you do your R&D in the Maldives??'), it has and does happen.

However, it is changing. Relationships are still going to be important. You need to be trusted to do business here, but don't get relationships confused with corruption. Will a $75 bottle of wine from California that you brought over be appreciated by a potential client? Yes of course, and it will help develop that relationship as it would with any other friend or acquaintance.

And you should think about it from that perspective: would you pay for a friend to go to London so that he would be a better friend? Well I suppose you could, but I would guess that's not a very deep friendship based on mutual trust. Much better to spend the time to get to know the client, show your commitment, and as trite as it sounds, become a 'trusted advisor'. Reasonable gifts do have their place as they do in any relationship. 

In a very brief conclusion, China is not an easy place to do business, but it is an important place to do business and you need to come in with your eyes open. Awareness is key. Complicity is not. 


Kapronasia Newsletter

Sign up for our email list and stay up to date with our latest insights.